Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 1,541 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.87, for a total value of $235,572.67. Following the completion of the transaction, the chief executive officer now directly owns 136,778 shares in the company, valued at approximately $20,909,252.86. This represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kyle Gano also recently made the following trade(s):

• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00.

Neurocrine Biosciences Trading Up 1.5 %

Shares of NBIX traded up $2.32 during trading hours on Tuesday, hitting $152.42. 814,308 shares of the stock traded hands, compared to its average volume of 950,096. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The firm has a market capitalization of $15.43 billion, a PE ratio of 40.86 and a beta of 0.33. The business has a fifty day moving average of $137.92 and a 200-day moving average of $131.51.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NBIX. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Wedbush restated an “outperform” rating and set a $148.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Morgan Stanley boosted their price objective on Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Raymond James reaffirmed an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $166.85.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently made changes to their positions in the company. State Street Corp lifted its stake in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after acquiring an additional 539,936 shares during the period. Geode Capital Management LLC increased its holdings in Neurocrine Biosciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock valued at $213,773,000 after purchasing an additional 39,610 shares during the last quarter. Braidwell LP increased its holdings in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after purchasing an additional 158,665 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Neurocrine Biosciences by 1.4% in the fourth quarter. Bank of New York Mellon Corp now owns 870,290 shares of the company’s stock valued at $118,795,000 after purchasing an additional 12,040 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in Neurocrine Biosciences by 145.1% in the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after purchasing an additional 485,894 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.